Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
Authors
- Chiadi E. Ndumele (ORCID: https://orcid.org/0000-0002-1603-282X)
- Dhruv S. Kazi (ORCID: https://orcid.org/0000-0002-9510-2979)
- Sadiya S. Khan (ORCID: https://orcid.org/0000-0003-0643-1859)
Institutions
- Northwestern University (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Deaconess Hospital (US)
Publication Details
- Journal
- JAMA
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1001/jama.2024.22284
- Citations
- 41
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 14.67